

Name of the Issuer:		Achyut Healthcare Limited	Last updated on	October 31, 2022
1	Type of Issue (IPO / FPO) IPO			
2	Issue Size (Rs. Cr)* - Fresh Issue Size (Rs. Lakhs) <i>*Source: Prospectus dated March 11, 2022 and Final Post issue report dated March 30, 2022</i>		360.00	
3	Grade of issue along with name of the rating agency Name Grade		Not Applicable Not Applicable	
4	Subscription Level (Number of times) <i>Source: Final Post issue report dated March 30, 2022</i> <i>*The above figure is after technical rejections</i>		2.55*	
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges			
Particulars		%		
(i) allotment in the issue <sup>(1)</sup>		0.00%		
(ii) at the end of 1st Quarter immediately after the listing <sup>(2)</sup>		0.00%		
(iii) at the end of 1st FY (March 31, 2022) <sup>(2)</sup>		0.00%		
(iv) at the end of 2nd FY (March 31, 2023) (2)		0.00%		
(v) at the end of 3rd FY (March 31, 2024)		0.00%		
<i>*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.</i>				
<i>(1) Source: Basis of Allotment</i>				
<i>(2) Source: Shareholding pattern as available on BSE</i>				
6	Financials of the issuer (Consolidated)			
		(In Rs. Lacs)		
Parameters	1st FY (March 31, 2022) <sup>(1)</sup>	2nd FY (March 31, 2023)	3rd FY (March 31, 2024)	
Income from operations	404.93	-	-	
Net Profit for the period	4.02	-	-	
Paid-up equity share capital	674.10	-	-	
Reserves excluding revaluation reserves	-	-	-	
<i>*Financials not disclosed as reporting for the relevant fiscal year has not been completed.</i>				
<i>(1) Source: Annual Report of the Company for relevant FY.</i>				
7	Trading Status in the scrip of the issuer Company's Equity Shares are listed on BSE Limited (SME Platform) The Shares have not been suspended or delisted.			
Particulars		Status		
(i) at the end of 1st FY (March 31, 2022)*		Frequently Traded		
(ii) at the end of 2nd FY (March 31, 2023)*				
(iii) at the end of 3rd FY (March 31, 2024)*				
<i>*Trading status not disclosed as the relevant fiscal year has not been completed.</i>				
8	Change in Directors of issuer from the disclosures in the offer document			
Particulars	Name of the Director	Appointed / Resigned		
(i) at the end of 1st FY (March 31, 2022)*	-	-		
(ii) at the end of 2nd FY (March 31, 2023)*	-	-		
(iii) at the end of 3rd FY (March 31, 2024)*	-	-		
Source: Stock Exchange Filings				
* Changes in Directors of Issuer not updated as the relevant financial years have not been completed				

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

(i) as disclosed in the offer document

(Rs. Crore)

Objects of the Fresh Issue	Amount
Funding purchase of machineries and equipment	2.76
General Corporate Purpose	0.59
Issue related expense	0.25
<b>Total</b>	<b>3.35</b>

Source: Prospectus dated March 11, 2022

(ii) Actual utilization

(Rs. Crore)

Objects of the Fresh Issue	Amount
Funding purchase of machineries and equipment	-
General Corporate Purpose	0.59
Issue related expense	0.25
<b>Total</b>	

Source: BSE Filing

(iii) Reasons for deviation, if any

Not applicable

(a) Comments on use of funds
------------------------------

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document

(c) Any other reservations expressed by the monitoring agency about the end use of funds

Not Applicable, since Issue size is less than Rs. 100 crores

Issue Price (Rs.):	20
Designated Stock Exchange:	BSE
Listing Date:	30-Mar-22

Price parameters	At close of listing day (March 30, 2022)	At close of 30th calendar day from listing day (April 28, 2022) <sup>(1)</sup>	At close of 90th calendar day from listing day (June 28, 2022) <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2022) <sup>(3)</sup>		
				Closing price	High	Low
					(during the FY)	(during the FY)
Market Price on BSE	21.15	20.00	20.95	20.55	20.55	20.55
BSE SENSEX*	58,683.99	57,521.06	53,177.45	58,568.51	61,765.59	47,705.08

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2023)			As at the end of 3rd FY after the listing of the issue (March 31, 2024)		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on BSE						
BSE SENSEX*						

\*Being index of BSE, the designated stock exchange

**Note:**

*(1) 30th calendar day shall be taken as listing date plus 29 calendar days.*

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

### 13 Basis for Issue Price

Accounting ratio	Name of the Company	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2022)*	At the end of 2nd FY (March 31, 2023)**	At the end of 3rd FY (March 31, 2024)**
EPS	Issuer	0.3	0.15	Not Available	Not Available
	Peer : Earum Pharmaceuticals Limited	0.028	0.36	Not Available	Not Available
	Vaishali Pharma Limited	0.99	3.82	Not Available	Not Available
	Chandra Bhagat Pharma Limited	0.25	1.06	Not Available	Not Available
	Industry Avg:	0.42	1.75	Not Available	Not Available
Price to Earnings Ratio (P/E)	Issuer	66.67	137.00	Not Available	Not Available
	Peer : Earum Pharmaceuticals Limited	229.29	193.57	Not Available	Not Available
	Vaishali Pharma Limited	56.57	66.82	Not Available	Not Available
	Chandra Bhagat Pharma Limited	474.00	107.35	Not Available	Not Available
	Industry Avg:	253.28	122.58	Not Available	Not Available
RoNW(%)	Issuer	3.41	0.44	Not Available	Not Available
	Peer : Earum Pharmaceuticals Limited	0.61	13.27	Not Available	Not Available
	Vaishali Pharma Limited	4.63	15.27	Not Available	Not Available
	Chandra Bhagat Pharma Limited	0.73	10.55	Not Available	Not Available
	Industry Avg:	1.99	13.03	Not Available	Not Available
NAV	Issuer	8.68	13.48	Not Available	Not Available
	Peer : Earum Pharmaceuticals Limited	4.70	13.56	Not Available	Not Available
	Vaishali Pharma Limited	4.63	24.90	Not Available	Not Available
	Chandra Bhagat Pharma Limited	34.29	35.35	Not Available	Not Available
	Industry Avg:	60.24	24.60	Not Available	Not Available

#### Notes:

(1) Sourced from Prospectus dated March 11, 2022.

\* The relevant data is not available yet.

\*\*Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.

(ii) NAV per share - Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal

(iii) P/E - Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal

(iv) RoNW - Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

(v) The company believes that there are no listed Companies in India which are focused exclusively on the segment in which they operate.

### 14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement			
19-10-2022	Statement Of Deviation (S) Or Variation(S) Under Regulation 32 Of SEBI (LODR) Regulations, 2015 As On 30th September, 2022.			

#### Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Shreni Shares Private Limited ("Shreni") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, Shreni does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither Shreni nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement.

<b>Prospectus</b>	<b>Monday, January 18, 2021</b>	<b>Wednesday, December 29, 2021</b>
Oswald Rosario Dsouza	Y	Y
Felix Shridhar Kadam	Y	Y
Janet O D'Souza	Y	Y
Christbell F Kadam	Y	Y
Anil Vasudev Kamath	Y	Y
Edwin E R Cotta	Y	Y
Ashley Mathew		

Friday, June 17, 2022

	Y
	Y
	Y
	Y
	N
	Y
Y	

<b>Particulars</b>	<b>Cospower Engineering limited 2022</b>		
<b>Equity Share Capital</b>	15,000,000		
<b>Reserve and Surplus</b>	53,991,000		
<b>Networth</b>	68,991,000		
<b>Net Profit</b>	7,467,000		
<b>EPS</b>	4.98		
<b>Market Price as on 31.03.2022 (Closing Price)</b>	67.5		
<b>P/E Ratio</b>	13.56		
<b>NAV</b>	45.99		
<b>No. of shares</b>	1,500,000		
<b>Face Value</b>	10		
<b>RoNW</b>	10.82		
nw			
<b>No. of shares</b>	1,500,000		
<b>NAV</b>	#DIV/0!		



[illegible]